Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2441-2450 Newer>

BusinessWeek October 31, 2005 Spencer E. Ante	Crashing The Stent Party Conor Medsystems is trying to take on Goliaths J&J and Boston Scientific.
BusinessWeek October 31, 2005 Gene G. Marcial	Why Biocryst Has Wings Shares of the pharmaceutical are on fire, soaring from $4.39 a share in early April to $15 on Oct. 19.
The Motley Fool October 20, 2005 Stephen D. Simpson	Pfizer Fizzles Disappointing guidance could have this giant pharmaceutical company retesting its lows. This is likely a good time for long-termers to do their due diligence, since they'll probably have some time to get into the stock.
The Motley Fool October 20, 2005 Stephen D. Simpson	Baxter Needs Growth Infusion This is a fine health-care company, but a sluggish top line suggests there are limits to how far it can go. Trading at nearly 20 times forward earnings, it seems like expectations of a growth revival are already in the stock.
The Motley Fool October 20, 2005 Stephen D. Simpson	Wide Eyes at Alcon Excellent margin performance fueled exceptional growth for this eye-care titan. This is a strong and valuable cash-producing franchise, and it deserves a premium valuation -- but how much of a premium?
The Motley Fool October 20, 2005 Stephen D. Simpson	Lilly Steady As She Goes In-line performance is probably the best that investors in this pharmaceutical could have hoped for this quarter.
The Motley Fool October 20, 2005 Brian Gorman	Amgen's Drive to Diversify The drugmaker pulled in impressive results with its current portfolio, but a drug in late-stage testing could make the company even more attractive to investors.
The Motley Fool October 19, 2005 Stephen D. Simpson	Stryker Still on Target The ever-present 20% growth target will get tougher to hit, but this is a quality medical company. Investors, take note.
The Motley Fool October 19, 2005 Stephen D. Simpson	ICU, You Look Healthier An incredible third quarter shows what operating leverage can do for this little medical technology company. Investors, take note.
The Motley Fool October 19, 2005 Stephen D. Simpson	Abbott Still a Little Pale Perhaps drug and device pipelines, plus margin improvements, can put some color back into the diversified health-care company's stock.
<Older 2441-2450 Newer> Return to current articles.